RTA Laboratuvarlari Biyolojik (RTALB) fair value: what the stock is really worth
We calculate from audited financials what RTA Laboratuvarlari Biyolojik is really worth. The fair value tells you whether the price is too high or too low, the quality score (0 to 100) how solid the business behind it is. 26 models, 37 quality factors, updated daily.
Watch RTA Laboratuvarlari Biyolojik for free, get notified when fair value or trend changes. Plus fair value for all 35,000+ stocks, 14 days of Pro free, no card.Watch for free
69 individual criteria per stock, every one traceableSee the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Sep 13, 2026.
How to read this chart
60‑month range 1.16 TRY – 5.92 TRY · fair‑value band 2.32 TRY – 5.50 TRY · the 3.03 TRY price screens below the 3.56 TRY fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). Dashed = 300-day average. As of Sep 13, 2026.
RTA Laboratuvarlari Biyolojik Urunler Ilac ve Makine Sanayi Ticaret A.S. engages in the research, development, and production of microbiology and molecular biology products in Turkey.
Show more
RTA Laboratuvarlari Biyolojik Urunler Ilac ve Makine Sanayi Ticaret A.S. engages in the research, development, and production of microbiology and molecular biology products in Turkey. It offers real-time PCR kits, nucleic acid extraction kits, microbiology media, microbiology stains, and rapid tests; standards and reference materials, and membrane filters; chemicals and reactives, membrane filters, microbiology gas generators, and other consumables; and instruments and consumables. RTA Laboratuvarlari Biyolojik Urunler Ilac ve Makine Sanayi Ticaret A.S. was incorporated in 1996 and is based in Kocaeli, Turkey.
Stock analysis
RTA Laboratuvarlari Biyolojik (RTALB) currently trades at 3.03 TRY, while our model-based Fair Value estimate is 3.56 TRY, implying the stock looks roughly 14.9% undervalued today.
Show more
Valuation
Bull case: the Economic Profit group reads highest at a median of 18.11 TRY per share, and 16 of the 23 models we run sit above the 3.03 TRY price.
Bear case: the Multiples group reads lowest at 1.68 TRY, and 7 of the 23 models stay below the price. Evidence for this calculation is low.
Scenario range: 2.32 TRY (bear) to 5.50 TRY (bull), the price of 3.03 TRY sits inside it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 57/100 (solid quality), in the Healthcare sector.
Weak Growth: Revenue growth is weak: less than 2 % a year.
RTA Laboratuvarlari Biyolojik reported revenue of 240M TRY in FY2025 versus 384M TRY in FY2021, a compound −11.1%/yr. Reported net income was 881M TRY in FY2025, compounding +66.6%/yr from FY2021.
Key figures
Market cap 1.5B TRY (≈ $31.2M) · P/E ratio 5.1 · P/S ratio 18.6 · EPS (TTM) 0.6000 TRY · Dividend yield 0.1% · Net margin 119% · Return on equity 12.4% · Return on assets (EBIT) 2.2%.
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 50 out of 100 (low confidence).
What moves the price
The share trades about 40% below its 52-week high and 1% above its 52-week low, currently below its 200-day average.
For context, the median of 10 Healthcare peers we cover trades at −7% fair-value upside, at 17%, RTALB screens cheaper than that median.
Fair Value models
Bear 2.32 TRYFair Value 3.56 TRYBull 5.50 TRY
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above is their evidence-weighted blend, not the output of a single model. Based on fiscal year 2025 figures (about 8 months old). Earnings retained since then (0.4241 TRY per share) are deliberately not added.Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target.Evidence ⓘEvidence = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card.40/100
Revenue growth is weak: less than 2 % a year.
Revenue growth 1 year
+15.4%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+40.7%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+0.8%
Revenue growth 15 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+23.1%
’14
’15
’16
’17
’18
’19
’20
’21
’22
’23
’24
’25
What shareholders gained per year (last 5 years), in TRY ⓘWhat the business itself delivers per year: earnings growth per share plus the dividend yield. This is what you get IF the market keeps valuing the stock the same way: it contains no assumption about the market changing its mind. Computed per share, so buybacks count and a merger does not pass as growth. For a company that pays no dividend it is pure earnings growth per share. Period: earnings growth per share as CAGR over the last 5 reported fiscal years (annual statements), plus the current dividend yield. The start value is the median of the three years around the start, so a single crisis year (a pandemic or a write-down) does not distort the rate. Measured in TRY: this currency has depreciated against the euro and dollar over the long run, so part of the nominal rate is currency erosion that never reaches a EUR/USD investor.
+3.6%
Earnings growth per share plus dividend.
Earnings per share, growth per year+3.5%
Dividend (yield on the price)0.1%
Profit margin 2020 to 2025 ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.31% → −7%
⚠ Revenue per share shrinking 10.6%/yr over ~6Y (margin trend unclear) ⓘStructural-decline marker: revenue PER SHARE has fallen over the last decade (robust median trend, not a single year). Backtested across 2005 to 2017, such businesses trailed the market by about 2.5 percentage points per year. Display only: it does not change the fair value or the quality score.
Growth Forecast
A lot of optimism in the price
The price assumes more growth than the company has delivered so far.
What the price assumes ⓘThis turns our valuation around: instead of asking what the share is worth, it asks what growth the current price requires. It uses the cash the company keeps after all spending (free cash flow), the same discount rate as our models, five years of growth, then slowing evenly to 2 % a year by year ten. Compared with the analysts' sales forecasts extended to the same five years (at least three analysts, for context only, it does not enter the Fair Value): within 3 percentage points counts as "in line" (amber), below that little optimism (green), above that a lot of optimism (red).
+8.6%
Yearly growth needed for the next five years to justify today's price.
Compare RTA Laboratuvarlari Biyolojik with another stock
Price, fair value, quality and upside side by side.
Free, no sign-up
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Biotechnology · 643 stocks
Beats the industry median on 10/14 measures
Overall it ranks above its industry peers.
Valuation
Quality Score57 · Above median
Fair Value upside+29% · Top 25%
Profitability
Return on equity (TTM)12% · Top 25%
Return on assets0% · Above median
Net margin (TTM)119% · Top 25%
Operating margin (TTM)0% · Below median
Growth and dividend
Revenue growth21% · Above median
Dividend yield (TTM)0.1% · Bottom 25%
Balance sheet
Debt / equity0.01× · Below median
Valuation Multiplesvs Biotechnology median · lower = cheaper
For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.
Is RTA Laboratuvarlari Biyolojik (RTALB) overvalued or undervalued?
As of Sep 13, 2026, our model estimates a fair value of 3.56 TRY versus a price of 3.03 TRY, about +17% upside (undervalued).
What is the fair value of RTALB?
Our model-based fair value for RTA Laboratuvarlari Biyolojik is 3.56 TRY (as of Sep 13, 2026), built from audited fundamentals. The current price: 3.03 TRY.
What is the quality score of RTALB?
RTA Laboratuvarlari Biyolojik has a Quality Score of 57/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for RTA Laboratuvarlari Biyolojik (RTALB)?
Our model-based price target is the fair value of 3.56 TRY (as of Sep 13, 2026) from 23 valuation models. Cautious scenario 2.32 TRY, optimistic scenario 5.50 TRY. It is a calculation from audited fundamentals, not an analyst target.
What is the RTA Laboratuvarlari Biyolojik stock forecast for 2026?
Our models put fair value at 3.56 TRY, about +17% upside versus a price of 3.03 TRY (undervalued). Cautious scenario 2.32 TRY, optimistic scenario 5.50 TRY. The calculation is refreshed regularly with new filings.
What is the revenue of RTA Laboratuvarlari Biyolojik (RTALB)?
RTA Laboratuvarlari Biyolojik reported trailing-twelve-month revenue of about 254M TRY (latest available figure, as of Sep 13, 2026).
Does RTA Laboratuvarlari Biyolojik pay a dividend?
RTA Laboratuvarlari Biyolojik currently shows a dividend yield of about 0.06% relative to its recent price (as of Sep 13, 2026).
What growth is priced into RTA Laboratuvarlari Biyolojik (RTALB)?
For today's price to be fair in a discounted-cash-flow model, RTA Laboratuvarlari Biyolojik would have to grow free cash flow by +8.6 % per year for five years (discount rate 12.7 %, then slowing evenly to 2 % perpetual growth by year ten). Over the last 5 years revenue grew +0.8 % per year. As of Sep 13, 2026.
What discount rate (WACC) does the fair value of RTALB use?
Our models discount RTA Laboratuvarlari Biyolojik at 12.7 %: a base by market capitalisation (nano), damped by beta 0.40, country premium for Turkey. The same rate applies in all 26 models.
What is a reverse DCF?
A reverse DCF turns the usual calculation around. Instead of deriving a value from assumptions, it takes today's price as given and asks: what free-cash-flow growth would a company have to deliver for exactly this price to be fair? The result is not a forecast but the expectation already priced in. For RTA Laboratuvarlari Biyolojik that is +8.6 % per year a year over ten years, using the same discount rate (12.7 %) and the same formula as our fair value.
How much growth has RTA Laboratuvarlari Biyolojik (RTALB) delivered so far?
Over the past 5 years revenue at RTA Laboratuvarlari Biyolojik grew +0.8 % a year. The price currently implies +8.6 % per year free-cash-flow growth a year. Comparing the two shows how much confidence is in the price: if it demands more than has been delivered, the business has to accelerate for the maths to work.
How fast is the sector of RTA Laboratuvarlari Biyolojik (RTALB) growing?
The median revenue growth in the sector is +4.3 % a year. That is the yardstick for the growth priced into RTA Laboratuvarlari Biyolojik (+8.6 % per year a year): it shows whether the expectation is within the usual range or beyond it.
What is the free cash flow yield of RTA Laboratuvarlari Biyolojik (RTALB)?
The free-cash-flow yield on the price is 7.98 %: that much free cash flow RTA Laboratuvarlari Biyolojik produces per unit of market value. When it exceeds the discount rate of our models (12.7 %), the business already earns more than its cost of capital demands, and the price needs little additional growth.
What is the intrinsic value of RTA Laboratuvarlari Biyolojik (RTALB)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For RTA Laboratuvarlari Biyolojik it is 3.56 TRY per share (as of Sep 13, 2026), against a price of 3.03 TRY. It is the blended result of 23 valuation models (cash flow, earnings, asset, dividend).
Is RTA Laboratuvarlari Biyolojik stock overvalued or undervalued in 2026?
As of Sep 13, 2026, RTALB trades below its calculated fair value: price 3.03 TRY, fair value 3.56 TRY, a gap of about +17% (undervalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of RTALB?
No. The price is what the market pays today (3.03 TRY); the fair value is what the company's own numbers justify (3.56 TRY). For RTA Laboratuvarlari Biyolojik the two are 0.5300 TRY per share apart. That gap is exactly why we show both numbers side by side.
How much is RTA Laboratuvarlari Biyolojik worth?
The market values RTA Laboratuvarlari Biyolojik at about 1.5B TRY (market capitalisation, as of Sep 13, 2026). Per share that is 3.03 TRY; our models calculate a fair value of 3.56 TRY per share.
What do the bullish and bearish scenarios say about RTALB?
Our models span a range for RTA Laboratuvarlari Biyolojik: cautious scenario 2.32 TRY, base 3.56 TRY, optimistic 5.50 TRY per share (as of Sep 13, 2026, price 3.03 TRY). The range comes from different growth and margin assumptions, not from analyst opinions.
What is the P/E ratio of RTALB?
RTA Laboratuvarlari Biyolojik trades at a price-to-earnings ratio of 5.1 (as of Sep 13, 2026). A P/E on its own says little: it compares the price with ONE year of profit, while our fair value of 3.56 TRY is built from several models across several years. Other multiples: P/B 0.5, P/S 6.0, EV/EBITDA 78.0.
How solid is the balance sheet of RTA Laboratuvarlari Biyolojik (RTALB)?
Balance-sheet figures for RTA Laboratuvarlari Biyolojik (as of Sep 13, 2026): return on equity 12.4%, debt of 0.01 per unit of equity. They feed the Quality Score of 57/100, which measures business quality independently of the share price.
How far is RTALB from its 52-week high?
RTA Laboratuvarlari Biyolojik trades at 3.03 TRY, about 40% below its 52-week high of 5.08 TRY and 1% above the low of 3.01 TRY (as of Sep 13, 2026). Distance from the high says nothing about value: that is what the fair value of 3.56 TRY is for.
Which stocks are comparable to RTA Laboratuvarlari Biyolojik?
From the same area (Healthcare) we also value Vertex Pharmaceuticals Incorporated, Regeneron Pharmaceuticals, Inc, argenx SE, BeOne Medicines AG, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is RTA Laboratuvarlari Biyolojik stock attractive at the current price?
The data as of Sep 13, 2026: price 3.03 TRY, calculated fair value 3.56 TRY (+17%), Quality Score 57/100, from 23 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of RTALB calculated?
We run RTA Laboratuvarlari Biyolojik through 23 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of 3.56 TRY, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 15.6 % above its aggregate fair value. RTA Laboratuvarlari Biyolojik currently trades 17 % below its own fair value, and the market average says nothing about that. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of RTA Laboratuvarlari Biyolojik (RTALB)?
The closing price on Sep 14, 2026 was 3.03 TRY. Our model-based fair value is 3.56 TRY, about +17% upside (undervalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with RTA Laboratuvarlari Biyolojik right now?
A fairly wide model range (2.32 TRY to 5.50 TRY) leaves room in how you read the outcome. Evidence is limited here (fewer models, shorter history), so the fair value is a rougher estimate than usual.
Key figures of RTA Laboratuvarlari Biyolojik
How large is the market capitalisation of RTA Laboratuvarlari Biyolojik (RTALB)?
The market capitalisation of RTA Laboratuvarlari Biyolojik is 1.5B TRY (≈ $31.2M). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of RTA Laboratuvarlari Biyolojik (RTALB)?
The price-to-sales ratio of RTA Laboratuvarlari Biyolojik is 18.6 (P/E × margin). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of RTA Laboratuvarlari Biyolojik (RTALB)?
Earnings per share at RTA Laboratuvarlari Biyolojik are 0.6000 TRY (price ÷ EPS = P/E 5.1). Earnings per share over the last twelve months: total profit spread across every single share.
What is the dividend yield of RTA Laboratuvarlari Biyolojik (RTALB)?
The dividend yield of RTA Laboratuvarlari Biyolojik is 0.1% (payout 0.3%). Yearly dividend relative to the share price. 3% pays 3 per 100 invested. Below: how much of profit is used for it.
What is the net margin of RTA Laboratuvarlari Biyolojik (RTALB)?
The net margin of RTA Laboratuvarlari Biyolojik is 119% (last twelve months). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of RTA Laboratuvarlari Biyolojik (RTALB)?
The return on equity (ROE) of RTA Laboratuvarlari Biyolojik is 12.4% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of RTA Laboratuvarlari Biyolojik (RTALB)?
On an EBIT basis the return on assets of RTA Laboratuvarlari Biyolojik is 2.2% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of RTA Laboratuvarlari Biyolojik (RTALB)?
The operating margin of RTA Laboratuvarlari Biyolojik is −0.1% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at RTA Laboratuvarlari Biyolojik (RTALB)?
Revenue at RTA Laboratuvarlari Biyolojik is growing +20.8% versus a year earlier (3y avg +40.7%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at RTA Laboratuvarlari Biyolojik (RTALB)?
Earnings per share at RTA Laboratuvarlari Biyolojik are growing +13.3% versus a year earlier. How much earnings per share grew versus a year earlier.
How much net debt does RTA Laboratuvarlari Biyolojik (RTALB) carry?
The net debt of RTA Laboratuvarlari Biyolojik is 109M TRY (fiscal year 2025, ≈ 0.9 yrs of FCF). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.
Free · no account needed
Watch RTA Laboratuvarlari Biyolojik in the live analysis
One click puts RTA Laboratuvarlari Biyolojik on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener. You can also try 14 days of Pro there, no card.
